辛伐他汀治疗肝硬化门静脉高压症的作用机制及应用现状

吴欢; 伍龙; 杨京

doi:10.3969/j.issn.1001-5256.2019.02.037

辛伐他汀治疗肝硬化门静脉高压症的作用机制及应用现状

DOI: 10.3969/j.issn.1001-5256.2019.02.037

1. 贵州医科大学附属医院感染科
2. 贵州医科大学附属医院肛肠外科

详细信息

中图分类号: R575.21
计量
- 文章访问数: 1693
- HTML全文浏览量: 55
- PDF下载量: 401
- 被引次数: 0
出版历程
- 收稿日期: 2018-09-17
- 出版日期: 2019-02-20

Mechanism and current status of simvastatin in treatment of cirrhotic portal hypertension

Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University

摘要

摘要: 门静脉高压症被认为是继病因之后推动肝功能减退的重要生理环节。通过对相关文献的归纳总结得出,与传统防治门静脉高压症药物相比,辛伐他汀可通过诱导Kruppel样因子2及一氧化氮的表达,达到改善肝功能及降低肝硬化门静脉压力的作用,分析表明辛伐他汀在改善肝硬化门静脉血流动力学方面有广泛应用前景。
- 肝硬化 /
- 门静脉高压症 /
- 辛伐他汀 /
- 治疗学 /
- 综述
Abstract: Besides related etiologies, portal hypertension ( PHT) is considered an important physiological link in promoting liver dysfunction. Literature review has shown that compared with the conventional drugs for the prevention and treatment of PHT, simvastatin can induce the expression of Kruppel-like factor-2 and nitric oxide to improve liver function and reduce cirrhotic portal venous pressure. Related analysis shows that simvastatin can be widely used in clinical practice to improve portal vein hemodynamics in cirrhotic patients.
- liver cirrhosis /
- portal hypertension /
- simvastatin /
- therapeutics /
- review

HTML全文

参考文献(36)

[1]WRIGHT AS, RIKKERS LF.Current management of portal hypertension[J].J Gastrointest Surg, 2005, 9 (7) :992-1005.

[2]POLLO-FLORES P, SOLDAN M, SANTOS UC, et al.Three months of simvastatin therapy vs.placebo for severe portal hypertension in cirrhosis:A randomized controlled trial[J].Dig Liver Dis, 2015, 47 (11) :957-963.

[3]ABRALDES JG, ALBILLOS A, BANARES R, et al.Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension:A randomized controlled trial[J].Gastroenterology, 2009, 136 (5) :1651-1658.

[4]ZHENG S, LIU H, YIN F, et al.Effects of simvastatin on portal blood flow and liver fibrosis indices in patients with liver cirrhosis[J].Chin Hepatol, 2011, 16 (1) :50-52. (in Chinese) 郑盛, 刘海, 殷芳, 等.辛伐他汀对肝硬化患者门脉血流及肝纤维化指标的影响[J].肝脏, 2011, 16 (1) :50-52.

[5]YANG YG.Simvastatin D with propranolol cirrhosis and portal hypertension in comparison[J].China Foreign Med Treatment, 2012, 31 (34) :95-96. (in Chinese) 杨玉贵.辛伐他丁与心得安治疗肝硬化门静脉高压症的比较[J].中外医疗, 2012, 31 (34) :95-96.

[6]de FRANCHIS R, BAVENO VIF.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.

[7]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Endoscopy, Chinese Medical Association.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J].J Clin Hepatol, 2016, 32 (2) :203-219. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志, 2016, 32 (2) :203-219.

[8]GLUUD LL, LANGHOLZ E, KRAG A.Meta-analysis:Isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices[J].Aliment Pharmacol Ther, 2010, 32 (7) :859-871.

[9]SALMERON JM, RUIZ DEL ARBOL L, GINES A, et al.Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis[J].Hepatology, 1993, 17 (5) :800-806.

[10]HERNANDEZ-GUERRA M, GARCIA-PAGAN JC, BOSCHJ.Increased hepatic resistance:A new target in the pharmacologic therapy of portal hypertension[J].J Clin Gastroenterol, 2005, 39 (4 Suppl 2) :s131-s137.

[11]SCHEPKE M, WIEST R, FLACKE S, et al.Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis:a placebo-controlled, double-blind study[J].Am J Gastroenterol, 2008, 103 (5) :1152-1158.

[12]GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, et al.Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J].N Engl J Med, 2005, 353 (21) :2254-2261.

[13]ROSMORDUC O.Antiangiogenic therapies in portal hypertension:A breakthrough in hepatology[J].Gastroenterol Clin Biol, 2010, 34 (8-9) :446-449.

[14]DEKKER RJ, van SOEST S, FONTIJN RD, et al.Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (KLF2) [J].Blood, 2002, 100 (5) :1689-1698.

[15]GRACIA-SANCHO J, RUSSO L, GARCIA-CALDERO H, et al.Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver[J].Gut, 2011, 60 (4) :517-524.

[16]DAS A, SHERGILL U, THAKUR L, et al.Ephrin B2/EphB4pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment[J].Am J Physiol Gastrointest Liver Physiol, 2010, 298 (6) :g908-g915.

[17]TRIPATHI DM, VILASECA M, LAFOZ E, et al.Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal[J].Gastroenterology, 2018.[Epub ahead of print]

[18]BOSCH J, ABRALDES JG, FERNANDEZ M, et al.Hepatic endothelial dysfunction and abnormal angiogenesis:New targets in the treatment of portal hypertension[J].J Hepatol, 2010, 53 (3) :558-567.

[19]CHEN CX.Role of nitric oxide in regulating hepatic and visceral vascular resistance[J].Chin Hepatol, 2000, 5 (2) :103-104. (in Chinese) 陈从新.一氧化氮在调节肝和内脏血管阻力中的作用[J].肝脏, 2000, 5 (2) :103-104.

[20]ABRALDES JG, RODRIGUEZ-VILARRUPLA A, GRAUPERAM, et al.Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4cirrhotic rats[J].J Hepatol, 2007, 46 (6) :1040-1046.

[21]ZAFRA C, ABRALDES JG, TURNES J, et al.Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J].Gastroenterology, 2004, 126 (3) :749-755.

[22]DENG ZY, LI J, JIN Y, et al.Effect of oxymatrine on the p38mitogen-activated protein kinases signalling pathway in rats with CCl4 induced hepatic fibrosis[J].Chin Med J, 2009, 122 (12) :1449-1454.

[23]TSUKADA S, WESTWICK JK, IKEJIMA K, et al.SMAD and p38 MAPK signaling pathways independently regulate alpha1 (I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells[J].JBiol Chem, 2005, 280 (11) :10055-10064.

[24]YUAN GQ, WANG LL, YANG HT, et al.The role of p38MAPKsignal pathway in the course of TNF-αinducing HUVEC to secrete ET-1 and e NOS and the effect of Tongxinluo[J].Chin Pharmacol Bull, 2009, 25 (11) :1415-1420. (in Chinese) 袁国强, 王玲玲, 杨海涛, 等.p38 MAPK通路在TNF-α诱导人脐静脉内皮细胞分泌ET-1与e NOS中的作用及通心络干预影响[J].中国药理学通报, 2009, 25 (11) :1415-1420.

[25]CHENG YF, ZHONG J, TANG SH, et al.Simvastatin lowers portal pressure in rats with cirrhosis and portal hy-pertension via inhibiting activation of p38 MAPK signaling pathway[J].Chin J Pathophysiol, 2013, 29 (2) :205-209. (in Chinese) 陈埏芳, 钟健, 汤绍辉, 等.辛伐他汀通过抑制p38 MAPK活化降低肝硬化门静脉高压大鼠门静脉压力[J].中国病理生理杂志, 2013, 29 (2) :205-209.

[26]HUANG HC, WANG SS, LEE JY, et al.Simvastatin effects on portal-systemic collaterals of portal hypertensive rats[J].JGastroenterol Hepatol, 2010, 25 (8) :1401-1409.

[27]OBERTI F, PILETTE C, RIFFLET H, et al.Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation[J].J Hepatol, 1997, 26 (6) :1363-1371.

[28]ZHANG SY, ZHAO SZ, JI KP, et al.Simvastatin D with propranolol cirrhosis and portal hypertension in comparison[J].China J Prac Med, 2012, 39 (6) :F0004. (in Chinese) 张素云, 赵树忠, 纪柯平, 等.辛伐他丁与心得安治疗肝硬化门静脉高压症的比较[J].中国实用医刊, 2012, 39 (6) :F0004.

[29]LI YT, TANG SH, LONG LJ, et al.The effects of statins in treatment of portal hypertension in cirrhotic patients and rats:A Meta-analysis[J].Chin J Difficult Comp Cases, 2017, 16 (9) :935-939. (in Chinese) 李玉婷, 汤绍辉, 龙林竞, 等.他汀类药物对肝硬化门静脉高压症疗效的Meta分析[J].疑难病杂志, 2017, 16 (9) :935-939.

[30]XU M, SUN S, FENG PP, et al.Effects of simvastatin on hepatic fibrosis in rats and its mechanism[J].Sci Technol Rev, 2010, 28 (24) :89-92. (in Chinese) 徐明, 孙申, 冯盼盼, 等.辛伐他汀对大鼠肝纤维化的影响及其作用机制[J].科技导报, 2010, 28 (24) :89-92.

[31]TREBICKA J, HENNENBERG M, ODENTHAL M, et al.Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells[J].J Hepatol, 2010, 53 (4) :702-712.

[32]CHENG YF.Effects of simvastatin on portal vein pressure and hepatic fibrosis in rats with cirrhosis and portal hypertension[D].Guangzhou:Jinan University, 2011. (in Chinese) 陈埏芳.辛伐他汀对肝硬化门静脉高压症大鼠门静脉压力及肝纤维化指标的影响[D].广州:暨南大学, 2011.

[33]SHI M, ZHENG H, NIE B, et al.Statin use and risk of liver cancer:An update meta-analysis[J].BMJ Open, 2014, 4 (9) :e005399.

[34]HSIANG JC, WONG GL, TSE YK, et al.Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population:A propensity score landmark analysis[J].J Hepatol, 2015, 63 (5) :1190-1197.

[35]MOMI S, IMPAGNATIELLO F, GUZZETTA M, et al.NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties[J].Eur J Pharmacol, 2007, 570 (1-3) :115-124.

[36]RODRIGUEZ S, RAURELL I, TORRES-ARAUZ M, et al.A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats[J].Sci Rep, 2017, 7:40461.

施引文献

资源附件(0)

访问统计